Katherine L. Pratt
Oregon Health & Science University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Katherine L. Pratt.
Hormone Research in Paediatrics | 2003
Karin A. Selva; Caroline K. Buckway; Gary Sexton; Katherine L. Pratt; Efi Tjoeng; Jaime Guevara-Aguirre; Ron G. Rosenfeld
Background/Aim: Insulin-like growth factor I (IGF-I) and insulin-lke growth factor binding protein 3 (IGFBP-3) generation tests are both sensitive and specific measures of growth hormone (GH) sensitivity. Recently, the question of reproducibility of IGF generation tests has been raised. We report our analysis of the correlation of low- and high-dose GH IGF-I and IGFBP-3 generation tests among patients with GH deficiency, GH insensitivity, and idiopathic short stature. Methods: A total of 198 subjects were randomized to either high- or low-dose GH for 7 days; the alternate dose was received after a 2-week washout period. Samples were collected at baseline and on days 5 and 8 of GH administration. Results: The serum concentrations of IGF-I and IGFBP-3 correlated significantly from one test to the other, regardless of the diagnosis. In normal subjects and patients with GH insensitivity and GH deficiency, the delta over baseline in IGF-I and IGFBP-3 in the low-dose test was highly predictive of the delta values in the high-dose test. The delta correlation was greatly diminished, however, in the patient population having idiopathic short stature. Conclusions: These observations support partial GH insensitivity effecting IGF-I generation specifically, as a possible etiology for idiopathic short stature, and thus such patients may warrant appropriate biochemical and/or molecular evaluation for partial GH insensitivity.
Diabetes | 2006
Abel López-Bermejo; Javad Khosravi; José Manuel Fernández-Real; Vivian Hwa; Katherine L. Pratt; Roser Casamitjana; Maria M. García-Gil; Ron G. Rosenfeld; Wifredo Ricart
IGF-binding protein (IGFBP)-related protein 1 (IGFBP-rP1) has been shown to bind both IGFs and insulin, albeit with low affinity, and to inhibit insulin signaling. We hypothesized that IGFBP-rP1 is associated with insulin resistance and components of the IGF system in humans. To this aim, a cross-sectional study was conducted in 113 nondiabetic and 43 type 2 diabetic men. Insulin sensitivity (insulin sensitivity index [Si] from intravenous glucose tolerance tests in nondiabetic subjects, or the rate constant for disappearance of glucose [KITT] from insulin tolerance tests in type 2 diabetic subjects), circulating IGFBP-rP1 (from enzyme-linked immunosorbent assay), adiponectin (from radioimmunoassay), C-reactive protein (CRP; from immunoturbidimetry), soluble tumor necrosis factor receptor 2 (sTNFR2; from enzyme-amplified sensitivity immunoassay), and IGF system parameters (IGF-I, free IGF-I, and IGFBP-1 from immunoradiometric assay) were assessed in all subjects. Among nondiabetic men, those in the highest quartile for circulating IGFBP-rP1 exhibited decreased Si and adiponectin (both P < 0.01) as well as increased CRP and sTNFR2 (both P < 0.05). Circulating IGFBP-rP1 was also found to be increased in previously undiagnosed type 2 diabetic patients (P = 0.01) but not in known type 2 diabetic patients receiving pharmacological therapy. Although no changes in IGF system components were evident by IGFBP-rP1 quartiles in nondiabetic subjects, independent positive associations of IGFBP-rP1 with circulating fasting IGFBP-1 were evident after adjustment for insulin resistance parameters in both nondiabetic and type 2 diabetic subjects, with IGFBP-rP1 explaining 2 and 11% of IGFBP-1 variance, respectively. In additional multivariate analyses, Si, sTNFR2, and age stood as independent predictive variables of IGFBP-rP1 (together explaining 18% of its variance) in nondiabetic subjects, and BMI became the only independent predictive variable of IGFBP-rP1 (explaining 26% of its variance) in type 2 diabetic men. These findings show for the first time that circulating IGFBP-rP1 is increased with insulin resistance, and they also suggest novel interactions between IGFBP-rP1 and the IGF system in humans.
Hormone Research in Paediatrics | 2009
Anna M. Aalbers; Daisy Chin; Katherine L. Pratt; Brian M. Little; Stuart J. Frank; Vivian Hwa; Ron G. Rosenfeld
Background/Aims: Circulating growth hormone-binding protein (GHBP), in humans, is the proteolytic product of the growth hormone receptor (GHR). We investigated a prepubertal male subject who was of short stature, but who had a markedly elevated serum level of GHBP. Methods: Serum and DNA from the patient and his mother were analyzed. Results: Both the patient and mother had serum GHBP concentrations over 100-fold higher than normal, by assays, and Western and ligand blot analysis. Sequencing of the GHR gene revealed a novel heterozygous C>A transversion at position 785-3 in the acceptor splice site of intron 7. Conclusion: In silico analysis of the altered sequence suggested that 785-3(C>A) is a splicing mutation, with either retention of intron 7 or the skipping of exon 8. The consequence is a truncated GHR lacking the transmembrane domain (encoded by exon 8) and the cytoplasmic domain. We hypothesize that this GHR variant cannot anchor to the cell membrane, and the continual secretion into the circulation explains the elevated levels of serum GHBP detected in the patient and his mother. Despite this mutation, the presence of the wild-type GHR allele, presumably, permits some normality in GH-induced action.
Journal of Pineal Research | 1996
Aaron Clemons; Jon F. Geffen; Joanne M. Otto; Katherine L. Pratt; Christian T. Harker
Abstract: Melatonin research has primarily utilized blood as the source of samples, but there is now increasing interest in measuring levels of the hormone found in saliva. One impediment to this approach is that several melatonin assays involve a column‐extraction step that can prove very time‐consuming or even impossible when salivary samples are excessively viscous. We have treated 67 samples with dithiothreitol to enhance their passage through the column. Following this treatment, all samples passed freely through the columns. The minimum and maximum values measured were 0.7–50.0 pg/ml for the untreated controls and 1.0–51.9 pg/ml for the treated samples. The means (± SEM) for these groups were 9.5 ± 1.6 and 9.9 ± 1.7, respectively, and were not significantly different from one another as assessed by Students t‐test (P = 0.08). In summary, we have found that this technique permits us to obtain values on samples which would otherwise be unusable and that such treatment does not alter the melatonin values yielded by RIA analysis.
The New England Journal of Medicine | 2003
Eric M. Kofoed; Vivian Hwa; Brian M. Little; Kathryn (Katie) Woods; Caroline Buckway; Junko Tsubaki; Katherine L. Pratt; Liliana Bezrodnik; Héctor G. Jasper; Alejandro Tepper; J J Heinrich; Ron G. Rosenfeld
The Journal of Clinical Endocrinology and Metabolism | 2003
Andrea M. Haqq; I. Sadaf Farooqi; Stephen O’Rahilly; Diane Stadler; Ron G. Rosenfeld; Katherine L. Pratt; Stephen H. LaFranchi; Jonathan Q. Purnell
Proceedings of the National Academy of Sciences of the United States of America | 2000
Zhiyong Wang; David W. Rose; Ola Hermanson; Forrest C. Liu; Thomas Herman; Wei Wu; Daniel P. Szeto; Anatoli S. Gleiberman; Anna Krones; Katherine L. Pratt; Ron G. Rosenfeld; Christopher K. Glass; Michael G. Rosenfeld
The Journal of Clinical Endocrinology and Metabolism | 2005
Vivian Hwa; Brian M. Little; Pelin Adiyaman; Eric M. Kofoed; Katherine L. Pratt; Gönül Öcal; Merih Berberoglu; Ron G. Rosenfeld
The Journal of Clinical Endocrinology and Metabolism | 2003
Andrea M. Haqq; Diane Stadler; Ron G. Rosenfeld; Katherine L. Pratt; David S. Weigle; R. Scott Frayo; Stephen H. LaFranchi; David E. Cummings; Jonathan Q. Purnell
The Journal of Clinical Endocrinology and Metabolism | 2001
P. Marzullo; Carolina Di Somma; Katherine L. Pratt; Javad Khosravi; Anastasia Diamandis; Gaetano Lombardi; Annamaria Colao; Ron G. Rosenfeld